Dec 11, 2020
Brain Scientific (OTCQB: BRSF), a commercial-stage health-care company focused on developing innovative and proprietary medical devices and software, recently entered into a strategic partnership with the Dalmore Group. A member of FINRA and SIPC, the Dalmore Group maintains an active presence in the Regulation A+ equity funding space. The company is one of the world’s most active broker-dealers and has served on more than 50 RegA+ offerings in the past 12 months, raising more than $1 billion of capital in 2019. The Dalmore Group secures the majority of its clients by referral from securities attorneys and industry participants. A recent article discussing this indicates that BRSF is looking to the company for its expert strategic advice and innovative solutions. “We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein of the collaboration. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states.”
To view the full article, visit https://ibn.fm/eRrYM
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion. InnoCare said it would use its...
At a zoo a short drive south of Bangkok, Charoon Youngprapakorn has spent a lifetime taking the pulse of Thailand’s tourism industry from an unlikely vantage point: the open jaws of crocodiles. Handlers at his Samut Prakan Crocodile Farm & Zoo have long thrilled onlookers by coaxing tips from the audience and carefully placing the money into the mouths of animals capable of taking off an entire hand. The crocodiles at this open-air, fan-cooled throwback to 1980s showmanship still take their tips...
President Trump pressed his personal brand of diplomacy as President Xi Jinping of China made his first trip to the White House in more than a decade.
Altman. Musk. Huang. Bezos. They all came to the White House Thursday night, though you might not have seen it on TV.
American chief executives turned out in force to see Xi Jinping, while their Chinese counterparts were absent, a sign of how drastically business ties have changed.
Xi Jinping, China’s leader, said two pandas would arrive soon at Zoo Atlanta. Panda diplomacy has been a cornerstone of U.S.-China relations.
Data centers, the Sovereign Wealth Fund, and a hydropower plant – will any of it better the lives of Mongolian people?
Pop star donations and state aid work together to give Seoul a durable bond with Nepal.
Xi’s U.S. visit was extensively covered by official outlets. It's much harder to gauge public opinion or even interest.
Both the South Korean government and the two former soldiers face an unprecedented resettlement process.
Easing tensions with Washington gives Beijing room to tackle economic troubles at home while reducing its vulnerability to American pressure.
And possibly makes history while doing so.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.